Yearly Archives: 2008

Apologies for light posting as of late. I’ve been buried deep in revisions to Building Biotechnology and prepping for an upcoming talk. Writing is coming to a close, so soon I’ll be looking for external reviewers and case study contributions.

For those of you attending BIO 2008, I’ll be presenting in a session on trends in biotechnology communication on Friday morning.

Title: Scientific Communications – Trends and Liabilities
Track: Public Relations/Investor Relations
Date and Time: Friday, June 20 9:00 AM – 10:30 AM

Looking forward to seeing old colleagues and meeting new friends BIO.

I’m also working on an interesting story I want to post on the blog shortly. It’s about the challenges of managing founder/board relations in building a biotechnology company. Stay tuned…

The March 2008 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract of each article:

Volume 14, Issue 2


Editorial PDF
Yali Friedman


Export compliance for life sciences PDF
John Avellanet
A new approach to improve technology commercialisation in university medical schools PDF
Courtney Price, Richard Huston, Arlen D Meyers
Biotechnology business models work: Evidence from the pharmaceutical marketplace PDF
J Leslie Glick
Valuing biotechnology companies: Does classification by technology type help? PDF
Jacqueline Loh, Robert Brooks
Risk management for the biotechnology industry: A Canadian perspective PDF
Sandra Vanderbyl, Sherry Kobelak
Singapore’s biomedical sciences landscape PDF
Keat-Chuan Yeoh
Social responsibility for the use of genes, genomes and biotechnology in biotechnology companies: A commentary from the bioethical viewpoint PDF
Yoshihiro Okada, Kazuo N Watanabe

Legal and Regulatory Updates

Legal and regulatory update PDF
Gerry Kamstra, John Wilkinson

Conference Report

Maryland and Virginia unite at 2007 Mid-Atlantic Bio Conference PDF
Harley King

Book Reviews

Book Review: Stem cell wars: Inside stories from the Frontlines PDF
Grant H Skrepnek


Courtesy of

Drug Patent Expirations in April 2008
*Drugs may be covered by multiple patents

Tradename Applicant Generic Name Patent Number Patent Expiration
ACTINEX Univ Az Cancer Ctr masoprocol 4,695,590 APR 17,2008
ACTINEX Univ Az Cancer Ctr masoprocol 5,008,294 APR 15,2008
ESTROSTEP 21 Warner Chilcott ethinyl estradiol; norethindrone acetate 5,010,070 APR 23,2008
ESTROSTEP FE Warner Chilcott ethinyl estradiol; norethindrone acetate 5,010,070 APR 23,2008
FEMPATCH Parke Davis estradiol 5,006,342 APR 09,2008
LODINE XL Wyeth Pharms Inc etodolac 4,966,768 APR 30,2008
ORFADIN Swedish Orphan nitisinone 5,006,158 APR 09,2008
ZEMURON Organon Usa Inc rocuronium bromide 4,894,369 APR 13,2008

Courtesy of

Two new biotechnology books:
I’m proud to announce two new books featuring international best practices in biotechnology business development and biotechnology education. These new books respectively empower industry leaders operating in the dynamic biotechnology industry, and help address the global shortage of skilled biotechnology workers.


First Edition, March 2008
Perfect Bound, 342 pages, US$74.95
ISBN: 978-09734676-7-3
Best Practices in Biotechnology Education
22 International Best Practices in K-12, College, Certificate, Master’s, Doctoral, MBA, Distance Education Programs and Student Groups
This international compilation is directed at faculty and program directors seeking to start or expand biotechnology education programs; policy makers and economic developers seeking to meet workforce needs; and, students, scientists, and business professionals looking to enter the biotechnology industry or upgrade their existing skills. The included cases describe a wide variety of international programs from high-school through Ph.D. levels, and student clubs. Some programs are in their first years whereas others are quite mature and have diversified to offer myriad degree and certificate programs.

First Edition, March 2008
Perfect Bound, 186 pages, US$67.95
ISBN: 978-09734676-0-4
Best Practices in Biotechnology Business Development
Valuation, Licensing, Cash Flow, Pharmacoeconomics, Market Selection, Communication, and Intellectual Property
Best Practices in Biotechnology Business Development provides a framework to understand critical issues in biotechnology business development. Experts from a wide range of disciplines have contributed best practices based on their experiences and expertise, enabling biotechnology entrepreneurs, senior managers, directors, and officers to develop a better understanding of the key elements in these operations, empowering them to better manage their implementation.
These books complement my recent title, Building Biotechnology:

Second Edition, August 2006
Hardcover, 320 pages, US$54.95
ISBN: 09734676-3-0
Building Biotechnology
Scientists know science; businesspeople know business.
This book explains both.

As biotechnology changes paradigms in medicine, agriculture, and industrial processes, there is a pressing need for cross-trained individuals capable of developing new innovations and bringing them to market. Building Biotechnology helps readers start and manage biotechnology companies and understand the business of biotechnology. This acclaimed book describes the convergence of scientific, political, regulatory, and commercial factors that drive the biotechnology industry and define its scope.

For more information, contact

Courtesy of

Drug Patent Expirations in March 2008
*Drugs may be covered by multiple patents

Tradename Applicant Generic Name Patent Number Patent Expiration
CARDIZEM CD Biovail diltiazem hydrochloride 5,002,776 MAR 26,2008
CARDURA XL Pfizer doxazosin mesylate 4,837,111 MAR 21,2008
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER Bayer Pharms ciprofloxacin 4,957,922 MAR 18,2008
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Bayer Pharms ciprofloxacin 4,957,922 MAR 18,2008
ESCLIM Women First Hlthcare estradiol 4,842,864 MAR 25,2008
IFEX Bristol Myers Squibb ifosfamide 4,882,452 MAR 03,2008
IFEX/MESNEX KIT Bristol Myers Squibb ifosfamide; mesna 4,882,452 MAR 03,2008
NEXIUM Astrazeneca esomeprazole magnesium 4,738,974 MAR 01,2008
NEXIUM Astrazeneca esomeprazole magnesium 4,783,974 MAR 01,2008
RESCULA R Tech Ueno Ltd unoprostone isopropyl 5,151,444 MAR 19,2008
SEMPREX-D Ucb Inc acrivastine; pseudoephedrine hydrochloride 4,650,807 MAR 26,2008
TOPROL-XL Astrazeneca metoprolol succinate 4,957,745 MARVariationen von <a href=”” mce_href=””>strip poker download</a>. 18,2008
TOPROL-XL Astrazeneca metoprolol succinate 5,001,161 MAR 18,2008
TOPROL-XL Astrazeneca metoprolol succinate 5,081,154 MAR 18,2008
UVADEX Therakos methoxsalen 4,999,375 MAR 12,2008
VIVELLE Novartis estradiol 4,814,168 MAR 04,2008
VIVELLE Novartis estradiol 4,994,267 MAR 04,2008
VIVELLE Novartis estradiol 4,994,278 MAR 04,2008
VUSION Barrier miconazole nitrate; petrolatum, white; zinc oxide 4,911,932 MAR 27,2008

Courtesy of

Guest content from John Avellanet, managing director and principal of Cerulean Associates:

John Avellanet

Follow-on biologics are a foregone conclusion in the US. Too much money is at stake. The more difficult discussion starts with how to prepare your company to compete.

Science Succumbs to Dollars
The financial pull on reimbursement organizations and the constituent push on Congress for less expensive biotechnology treatments will inevitably lead to a regulatory approval pathway for so-called follow-on or generic biologics.

I’ll be at Rutgers on February 29th, giving a talk on biotechnology entrepreneurship. My objective is to dispel the popular notions about how biotechnology entrepreneurship occurs, and to provide case studies demonstrating the diversity of methods by which biotechnology entrepreneurs start and build their businesses. I’ll also provide some case studies of significant mis-steps, with the intention of demonstrating that risks can come from many sources.

For more information, visit or contact the organizers at

The following appeal for generic biologic legislation was sent in from Insmed via youtube.

I’ve posted previously on the challenges of developing a framework for generic biologic approvals and questioned how much we can really expect to save. In the editorial for the upcoming issue of the Journal of Commercial Biotechnology, I argue that the United States is unlikely to lead in generic biologic regulation.

Got any ideas to overcome the challenges? I’d love to post them here or at the Journal of Commercial Biotechnology.